Campbell & CO Investment Adviser LLC Sells 24,624 Shares of Dynavax Technologies Corporation $DVAX

Campbell & CO Investment Adviser LLC trimmed its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX) by 38.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 39,769 shares of the biopharmaceutical company’s stock after selling 24,624 shares during the quarter. Campbell & CO Investment Adviser LLC’s holdings in Dynavax Technologies were worth $395,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Choreo LLC increased its position in Dynavax Technologies by 3.2% in the 1st quarter. Choreo LLC now owns 34,828 shares of the biopharmaceutical company’s stock valued at $452,000 after acquiring an additional 1,065 shares in the last quarter. Pacer Advisors Inc. acquired a new position in Dynavax Technologies during the 1st quarter worth $292,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Dynavax Technologies by 4.9% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,920 shares of the biopharmaceutical company’s stock valued at $401,000 after buying an additional 1,453 shares during the last quarter. Bryce Point Capital LLC acquired a new stake in shares of Dynavax Technologies in the 1st quarter valued at $357,000. Finally, XTX Topco Ltd increased its stake in shares of Dynavax Technologies by 57.0% in the 1st quarter. XTX Topco Ltd now owns 76,854 shares of the biopharmaceutical company’s stock valued at $997,000 after buying an additional 27,893 shares during the period. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Stock Down 0.9%

Dynavax Technologies stock opened at $11.06 on Monday. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -24.04 and a beta of 1.09. The company’s 50 day simple moving average is $10.13 and its 200 day simple moving average is $10.28. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.65 and a quick ratio of 6.01. Dynavax Technologies Corporation has a fifty-two week low of $9.20 and a fifty-two week high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. The company had revenue of $94.88 million for the quarter, compared to analysts’ expectations of $94.00 million. As a group, sell-side analysts anticipate that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Analysts Set New Price Targets

DVAX has been the topic of several research reports. Wall Street Zen raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th. Finally, JMP Securities reiterated a “market outperform” rating and set a $32.00 price target on shares of Dynavax Technologies in a research report on Friday, August 22nd. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Dynavax Technologies currently has a consensus rating of “Hold” and an average price target of $24.33.

Insiders Place Their Bets

In other Dynavax Technologies news, Director Scott Dunseth Myers purchased 3,800 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were bought at an average price of $10.82 per share, with a total value of $41,116.00. Following the completion of the transaction, the director directly owned 35,004 shares in the company, valued at $378,743.28. This trade represents a 12.18% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.98% of the company’s stock.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.